LOQTORZI

LOQTORZI is an FDA-registered drug product whose active ingredient is TORIPALIMAB-TPZI. It is labelled by Coherus Oncology, Inc. taken by intravenous and marketed as a human prescription drug product. Identifiers on file: NDC 70114-340, application BLA761240, label effective 20260723. This page reproduces the FDA-approved label text so you can check what a product is, who makes it and how it is supplied before discussing it with a pharmacist or prescriber.

Across FDA labelling, products containing TORIPALIMAB-TPZI are most often described in connection with: treatment adults, recurrent locally, unresectable metastatic, indicated combination, advanced nasopharyngeal, carcinoma npc, single agent, disease progression. Wording differs between labels, and the full indications section on this page takes precedence when it is present.

1 INDICATIONS AND USAGE LOQTORZI is a programmed death receptor-1 (PD-1)- blocking antibody indicated: in combination with cisplatin and gemcitabine, for first-line treatment of adults with metastatic or with recurrent locally advanced nasopharyngeal carcinoma (NPC) ( 1.1 ) as a single agent for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy ( 1.2 ) 1.1 First-line Treatment of Metastatic or Recurrent, Locally Advanced NPC with Cisplatin and Gemcitabine LOQTORZI is indicated, in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or with recurrent, locally advanced nasopharyngeal carcinoma (NPC). 1.2 Previously Treated Unresectable or Metastatic NPC LOQTORZI is indicated, as a single agent, for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.

2 DOSAGE AND ADMINISTRATION In combination with cisplatin and gemcitabine: 240 mg intravenously every three weeks ( 2.1 ) As a single agent: 3 mg/kg intravenously every two weeks ( 2.1 ) First Infusion : Infuse over 60 minutes. Subsequent Infusions : If no infusion-related reactions occurred during the first infusion, subsequent infusions may be administered over 30 minutes. 2.1 Recommended Dosage The recommended dosages of LOQTORZI are provided in Table 1. Administer as recommended [see Dosage and Administration (2.3) ]. Table 1: Recommended Dosage Indication Recommended Dosage of LOQTORZI Duration of Treatment First-line NPC 240 mg every three weeks Until disease progression, unacceptable toxicity, or up to 24 months. Recurrent NPC 3 mg/kg every two weeks Until disease progression or unacceptable toxicity. 2.2 Dosage Modifications No dose reductions of LOQTORZI are recommended. In general, withhold LOQTORZI for severe (Grade 3) immune-mediated adverse reactions. Permanently discontinue LOQTORZI for life-threatening (Grade 4) immune-mediated adverse reactions, recurrent severe (Grade 3) immune-mediated reactions that require systemic immunosuppressive treatment, or an inability to reduce prednisone to 10 mg per day or less (or equivalent) within 12 weeks of initiating steroids. Dosage modifications for LOQTORZI for adverse reactions that require management different from these general guidelines are summarized in Table 2. Table 2: Recommended Dosage Modifications for Adverse Reactions Adverse Reaction Severity Based on National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE) version 5.0 Dose Modification ALT=alanine aminotransferase, AST=aspartate aminotransferase, DRESS=drug rash with eosinophilia and systemic symptoms, SJS=Stevens Johnson syndrome, TEN=toxic epidermal necrolysis, ULN=upper limit of normal Immune-Related Adverse Reactions [see Warnings and Precautions (5.1) ] Pneumonitis Grade 2 Withhold Resume LOQTORZI in patients with complete or partial resolution to Grade 0-1 after corticosteroid taper. Permanently discontinue if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to 10 mg per day or less (or equivalent) within 12 weeks of initiating steroids. Grades 3 or 4 Permanently discontinue Colitis Grade 2 or 3 Withhold Grade 4 Permanently discontinue Hepatitis with no tumor involvement of the liver AST/ALT increases to more than 3 and up to 8 times ULN or Total bilirubin increases to more than 1.5 and up to 3 times ULN Withhold AST or ALT increases to more than 8 times ULN or Total bilirubin increases to more than 3 times ULN Permanently discontinue Hepatitis with tumor involvement of the liver If AST and ALT are less than or equal to ULN at baseline in patients with liver involvement, withhold or permanently discontinue LOQTORZI based on recommendations for hepatitis with no liver involvement. Baseline AST or ALT is more than 1 and up to 3 times ULN and increases to more than 5 and up to 10 times ULN or Baseline AST or ALT is more than 3 and up to 5 times ULN and increases to more than 8 and up to 10 times ULN Withhold Baseline AST or ALT is above the ULN and increases to more than 10 times ULN or Total bilirubin increases to more than 3 times ULN Permanently discontinue Endocrinopathies Grades 3 or 4 Withhold until clinically stable or permanently discontinue depending on severity Nephritis with Renal Dysfunction Grade 2 or 3 increased blood creatinine Withhold Grade 4 increased blood creatinine Permanently discontinue Exfoliative Dermatologic Conditions Suspected SJS, TEN, or DRESS Withhold Confirmed SJS, TEN, or DRESS Permanently discontinue Myocarditis Grades 2, 3, or 4 Permanently discontinue Neurological toxicities Grade 2 Withhold Grade 3-4 Permanently discontinue Other Adverse Reactions Infusion-related reactions [see Warnings and Precautions (5.2) ] Grade 1 or 2 Interrupt or slow the rate of infusion Grade 3 or 4 Stop infusion Permanently discontinue 2.3 Preparation and Administration Preparation for Intravenous Infusion Visually inspect the solution for particulate matter and discoloration. The solution is clear to slightly opalescent, colorless to slightly yellow. Discard the vial if visible particles are observed. Withdraw the required volume of LOQTORZI and inject slowly into a 100 mL or 250 mL infusion bag containing 0.9% Sodium Chloride Injection, USP. Mix diluted solution by gentle inversion. Do not shake. The final concentration of the diluted solution should be between 1 mg/mL to 3 mg/mL. Discard any unused portion left in the vial. Storage of Diluted Solution for Infusion LOQTORZI does not contain a preservative. If the diluted solution is not administered immediately, store either: At room temperature, 20°C to 25°C (68°F to 77°F), for no more than 8 hours from the time of dilution to the completion of the infusion. Discard diluted solution stored at room temperature after 8 hours. Or Refrigerated at 2°C to 8°C (36°F to 46°F) for no more than 24 hours from the time of dilution to the completion of the infusion. If refrigerated, allow the diluted solution to come to room temperature prior to administration. Discard the refrigerated diluted solution after 24 hours. Do not freeze. Administration Administer diluted solution intravenously via an infusion pump using an in-line aseptic filter (0.2 or 0.22 micron). First Infusion: Infuse over at least 60 minutes. Subsequent infusions: If no infusion-related reactions occurred during the first infusion, subsequent infusions may be administered over 30 minutes [see Dose Modifications (2.2) ]. Do not co-administer other drugs through the same intravenous line. When administered on the same day as chemotherapy, LOQTORZI should be administered prior to chemotherapy. Refer to the Prescribing Information for cisplatin and gemcitabine for recommended dosing information.

4 CONTRAINDICATIONS None . None

6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Severe and fatal immune-mediated adverse reactions [see Warnings and Precautions (5.1) ] Infusion-related reactions [see Warnings and Precautions (5.2) ] Complications of Allogeneic HSCT [see Warnings and Precautions (5.3) ] LOQTORZI in Combination with Cisplatin and Gemcitabine The most common adverse reactions (≥ 20%) are nausea, vomiting, decreased appetite, constipation, hypothyroidism, rash, pyrexia, diarrhea, peripheral neuropathy, cough, musculoskeletal pain, upper respiratory infection, insomnia, dizziness, and malaise. ( 6.1 ) LOQTORZI as a Single Agent The most common adverse reactions (≥ 20%) are fatigue, hypothyroidism and musculoskeletal pain. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Coherus Oncology, Inc. at 1-800-483-3692 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data described in the WARNINGS AND PRECAUTIONS section reflect exposure to LOQTORZI at a dose of 240 mg every 3 weeks in combination with up to 6 cycles of cisplatin and gemcitabine, followed by LOQTORZI 240 mg IV every 3 weeks, in 146 patients with NPC enrolled in a randomized, double-blind, placebo-controlled trial (JUPITER-02). Among the 146 patients, 73% were exposed to LOQTORZI for 6 months or more and 54% were exposed for 12 months or more. The most common adverse reactions (≥ 20%) were: nausea (71%), vomiting (68%), decreased appetite (55%), constipation (39%), hypothyroidism (38%), rash (36%), pyrexia (32%), diarrhea (31%), peripheral neuropathy (30%), cough (26%), musculoskeletal pain (25%), upper respiratory infection (23%), insomnia (23%), dizziness (21%), and malaise (21%). The most common Grade 3 or 4 laboratory abnormalities (≥2%) were: decreased neutrophils (58%), decreased lymphocytes (57%), decreased hemoglobin (50%) decreased platelets (33%), decreased potassium (10%), decreased sodium (9%), increased alanine aminotransferase (6%) increased or decreased magnesium (4.2% each), decreased calcium (3.5%), increased aspartate aminotransferase (2.7%), and bilirubin increased (2.1%). The data described in the WARNINGS AND PRECAUTIONS section also reflects exposure to LOQTORZI as a single agent at a dose of 3 mg/kg IV every 2 weeks in 851 patients enrolled in 12 trials: one randomized, active-controlled trial and 11 open-label, non-randomized trials. The tumor types included nasopharyngeal carcinoma (n=193) or other types of tumors (n=658). Among the 851 patients treated with LOQTORZI as a single agent, 35% were exposed for 6 months or more and 20% were exposed for 12 months or more. In this pooled safety population, the most common (≥20%) adverse reactions were: fatigue (22%), hypothyroidism (20%), and musculoskeletal pain (20%). The most common Grade 3 or 4 laboratory abnormalities (≥2%), were decreased sodium (9%), decreased lymphocytes (8%), decreased hemoglobin (7%), decreased fibrinogen (4.5%), increased lipase (4.0%), increased amylase (2.9%), decreased phosphate (2.8%), increased aspartate aminotransferase (2.6%), increased glucose (2.5%), and increased triglycerides (2.1%). First-line Treatment of Metastatic or Recurrent, Locally Advanced Nasopharyngeal Carcinoma (NPC) The safety of LOQTORZI in combination with cisplatin and gemcitabine was evaluated in JUPITER-02 [see Clinical Studies (14) ] . Key eligibility criteria were recurrent locally advanced or metastatic nasopharyngeal carcinoma (NPC) not previously treated with systemic chemotherapy for recurrent or metastatic disease. Patients with recurrent NPC after treatment with curative intent were required to have an interval of at least 6 months between the last dose of radiotherapy or chemotherapy and recurrence. Patients received LOQTORZI 240 mg (n=146) or placebo intravenously (IV) every 3 weeks (n=143), in combination with cisplatin 80 mg/m 2 IV every 3 weeks and gemcitabine 1000 mg/m 2 IV days 1 and 8 for up to 6 cycles followed by LOQTORZI 240 mg or placebo IV every 3 weeks until disease progression, unacceptable toxicity, or completion of 2 years of treatment. Among patients who received LOQTORZI, 73% were exposed for 6 months or longer and 54% were exposed for greater than one year. The median age of patients who received LOQTORZI was 48 years (range: 19 to 72), 83% male, 100% Asian, 60% had recurrent disease, and 40% presented with metastatic disease. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) was 0 (57%) or 1 (43%). Approximately 59% of patients had received at least one prior systemic therapy for locally advanced disease and 60% had received prior radiation therapy. Serious adverse reactions occurred in 43% of patients receiving LOQTORZI in combination with cisplatin and gemcitabine. Serious adverse drug reactions in ≥ 2% were thrombocytopenia (14%), neutrophil count decreased (10%), pneumonia (10%), anemia (9%), abnormal hepatic function (2.7%), and rash (2.1%). Of the patients who received LOQTORZI in combination with cisplatin and gemcitabine, there were three fatal adverse reactions (2.1%) one due to epistaxis; one due to intracranial hemorrhage associated with immune-related thrombocytopenia and coagulopathy; and one due to pneumonia. Permanent discontinuation of LOQTORZI, when given in combination with cisplatin and gemcitabine, due to an adverse reaction occurred in 12% of patients. Adverse reactions resulting in permanent discontinuation of LOQTORZI in ≥1% were pneumonia (2.1%), pulmonary tuberculosis (1.4%), rash (1.4%), and vomiting (1.4%). Dosage interruptions of LOQTORZI due to an adverse reaction occurred in 50% of patients. Adverse reactions which required dosage interruption in ≥2% were anemia (17%), decreased neutrophils (12%), thrombocytopenia (12%), acute kidney injury (4.1%), pneumonia (6%), fatigue (2.7%), upper respiratory infection (2.7%), and hypothyroidism (2.1%). Table 3 summarizes the adverse reactions in JUPITER-02. Table 3: Adverse Reactions (≥ 10%) in Patients with Recurrent, Locally Advanced or Metastatic NPC Who Received LOQTORZI in Combination with Cisplatin and Gemcitabine in JUPITER-02 Adverse Reaction NCI CTCAE v5.0. LOQTORZI Cisplatin/Gemcitabine N = 146 Placebo Cisplatin/Gemcitabine N = 143 All Grades (%) Grade 3 or 4 (%) All Grades (%) Grade 3 or 4 (%) Gastrointestinal Disorders Nausea 71 1.4 84 2.8 Vomiting 68 2.1 66 2.1 Constipation 39 0 46 0 Diarrhea 31 1.4 23 0 Stomatitis Includes mouth ulceration, stomatitis, and radiation stomatitis. 12 0 8 0.7 Metabolism and Nutrition Disorders Decreased appetite 55 0.7 63 0 Endocrine Disorders Hypothyroidism Includes hypothyroidism, tri-iodothyronine decreased, tri-iodothyronine free decreased, and thyroiditis. 38 0.7 17 0 Skin Disorders Rash Includes acneiform dermatitis, allergic dermatitis, catheter-site rash, dermatitis, drug eruption, eczema, erythema, macule, maculopapular rash, palmar-plantar erythrodysesthesia syndrome, papule, pruritic rash, rash, and urticaria. 36 3.4 28 2.8 Pruritus 17 0 8 0 General Disorders Pyrexia 32 1.4 24 0.7 Malaise 21 0.7 20 0 Fatigue Includes asthenia and fatigue. 19 0.7 22 2.1 Nervous System Disorders Peripheral neuropathy Includes hypoesthesia, neuralgia, neuropathy peripheral, paresthesia, peripheral sensory neuropathy. 30 0 31 0.7 Dizziness 21 0 22 0.7 Headache 18 0 23 0.7 Respiratory, Thoracic and Mediastinal Disorders Cough Includes cough and productive cough. 26 0 27 0 Musculoskeletal Disorders Musculoskeletal pain Includes back pain, bone pain, musculoskeletal chest pain, musculoskeletal pain, myalgia, neck pain, pain in extremity, pain in jaw. 25 0 25 0.7 Infections Upper respiratory infection Includes acute sinusitis, bronchitis, laryngitis, nasopharyngitis, pharyngitis, respiratory tract infection, rhinitis, sinusitis, and upper respiratory tract infection. 23 3.4 13 2.8 Pneumonia Includes aspiration pneumonia and pneumonia 18 11 7 3.5 Psychiatric Disorders Insomnia 23 0 17 0 Vascular Disorders Epistaxis 10 1.3 13 2.8 Hypertension Includes blood pressure increased, blood pressure systolic increased, hypertension, and hypertensive crisis. 10 6 6 4.2 Table 4 summarizes the laboratory abnormalities in JUPITER-02. Table 4: Select Laboratory Abnormalities (≥20%) That Worsened from Baseline in Patients with Recurrent, Locally Advanced or Metastatic NPC Who Received LOQTORZI in Combination with Cisplatin and Gemcitabine in JUPITER-02 Laboratory Abnormalities Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: LOQTORZI/chemotherapy (range: 139 to 146 patients) and placebo/chemotherapy (range: 136 to 143 patients). LOQTORZI Cisplatin/Gemcitabine Placebo Cisplatin/Gemcitabine All Grades Graded per NCI CTCAE v5.0; AKP=alkaline phosphatase. ALT=alanine aminotransferase. AST=aspartate aminotransferase. (%) Grade 3 or 4 (%) All Grades (%) Grades 3 or 4 (%) Hematology Decreased hemoglobin 94 50 97 38 Decreased neutrophils 91 58 95 63 Decreased lymphocytes 88 57 88 49 Decreased platelets 71 33 66 31 Chemistry Decreased magnesium 78 4.2 77 8 Decreased sodium 63 9 62 6 Increased alanine aminotransferase 58 6 50 3.5 Increased aspartate aminotransferase 58 2.7 53 4.9 Decreased albumin 49 0 48 0 Decreased calcium 45 3.5 46 4.2 Increased lactate dehydrogenase 42 0 35 0 Increased calcium 39 0 35 0.7 Decreased potassium 40 10 39 8 Increased creatinine 39 0.7 41 0 Increased alkaline phosphatase 27 0 27 0 Decreased glucose 23 1.4 16 0 Previously Treated, Unresectable or Metastatic Nasopharyngeal Carcinoma (NPC) The safety of LOQTORZI was evaluated in POLARIS-02. Eligible patients had previously treated unresectable or metastatic NPC. Patients received LOQTORZI 3 mg/kg every 2 weeks as an intravenous infusion until disease progression or unacceptable toxicity. Among patients who received LOQTORZI, 33% were exposed for 6 months or longer and 21% were exposed for greater than one year. The median age of patients who received LOQTORZI was 46 years (range: 22 to 71), 83% male, 100% Asian, Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 (35%) or 1 (65%) and median weight 59 kg (range: 32 to 101 kg). Serious adverse reactions occurred in 24% of patients who received LOQTORZI. Serious adverse drug reactions in (≥2%) were pneumonia (4.7%), abnormal hepatic function (2.6%), and hyperbilirubinemia (2.1%). Fatal adverse reactions occurred in 3.7% of patients who received LOQTORZI, including death not otherwise specified (1.6%), tumor hemorrhage (0.5%), hepatic failure and thrombocytopenia (0.5%), hyponatremia (0.5%), and sudden death (0.5%). Permanent discontinuation of LOQTORZI due to an adverse reaction occurred in 9% of patients. Adverse reaction resulting in permanent discontinuation of LOQTORZI in ≥1% included pneumonia (1.1%), abnormal hepatic function (1.1%), and hyperbilirubinemia (1.1%). Dosage interruptions due to an adverse reaction occurred in 23% of patients. Adverse reactions which required dosage interruption in ≥1% were pneumonia (2.1%), thrombocytopenia (2.1%), fatigue (1.6%), hyperbilirubinemia (1.6%), anemia (1.1%), decreased appetite (1.1%), abnormal hepatic function (1.1%), hypothyroidism (1.1%), and pneumonitis (1.1%). Table 5 summarizes the adverse reactions in POLARIS-02. Table 5: Adverse Reactions (≥10%) in Patients with Previously Treated, Unresectable or Metastatic NPC Who Received LOQTORZI in POLARIS-02 Adverse Reaction Toxicity was graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03. LOQTORZI N=190 All Grades (%) Grade 3 or 4 (%) Endocrine Disorders Hypothyroidism Includes hypothyroidism, thyroiditis, tri-iodothyronine decreased, and tri-iodothyronine free decreased 27 0 General Disorders Fatigue Includes fatigue and asthenia 22 2.6 Pyrexia 16 0 Respiratory Disorders Cough Includes cough and productive cough. 20 0 Musculoskeletal Disorders Musculoskeletal Pain Includes musculoskeletal pain and myalgia. 18 1.1 Metabolism and Nutrition Decreased Appetite 13 1.1 Gastrointestinal Disorders Constipation 11 0 Skin and Subcutaneous Disorders Pruritus 11 0 Rash Includes dermatitis allergic, eczema, and rash. 11 0 Investigations Weight Decreased 11 0 Table 6 summarizes the laboratory abnormalities in POLARIS-02. Table 6: Select Laboratory Abnormalities (≥20%) That Worsened from Baseline in Patients with Previously Treated, Unresectable or Metastatic NPC Who Received LOQTORZI in POLARIS-02 LOQTORZI All Grades (%) Toxicity graded per NCI CTCAE v4.03. The denominator used to calculate the rate varied from 141 to 186 based on the number of patients with a baseline value and at least one post-treatment value. Grade 3 or 4 (%) Chemistry Decreased albumin 38 0.5 Decreased sodium 35 11 Decreased phosphate 32 3.2 Increased aspartate aminotransferase 30 3.8 Decreased calcium 29 0.5 Increased alkaline phosphatase 28 2.2 Increased triglyceride 26 1.1 Increased glucose 24 1.1 Increased alanine aminotransferase 23 1.6 Hematology Decreased lymphocytes 52 9 Decreased hemoglobin 43 6

What is LOQTORZI used for?
1 INDICATIONS AND USAGE LOQTORZI is a programmed death receptor-1 (PD-1)- blocking antibody indicated: in combination with cisplatin and gemcitabine, for first-line treatment of adults with metastatic or with recurrent locally advanced nasopharyngeal carcinoma (NPC) ( 1.1 ) as a single agent for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or …

Who makes LOQTORZI?
Coherus Oncology, Inc. is the labeler of record for LOQTORZI.

What form does LOQTORZI come in?
administered by intravenous. Strengths and pack sizes vary by label, so compare the NDC on your pack with the identifier listed on this page.

Is LOQTORZI prescription or over-the-counter?
The FDA label for this product is recorded as human prescription drug. Marketing status can differ between strengths and countries, so check the dispensing rules where you live.

Has LOQTORZI been recalled?
No FDA recall record in our database matches this product name or manufacturer. Recall data is updated periodically, so a very recent notice may not appear here yet.

Where does this information come from?
All content is reproduced from FDA Structured Product Labelling data via openFDA. It is provided for identification and reference only and is not medical advice.